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Abstract The human p53 protein family comprises three
members ^ p53, p63 and p73. Whereas only one p53 variant is
known multiple isoforms of p63 and p73 have been described.
Depending on the isoform p63 influences p53-responsive genes in
a p53-like or -distinct manner. We have cloned multiple splice
variants of keratinocyte transcription factor (KET), the rat
ortholog of human p63. Several tissue specific variations of exon
1 resulting in different amino-terminal ends were identified.
Transactivation properties of the splice variants inversely
correlated with the length of the N-termini as determined by
activation of the p53-responsive p21 promotor. Multiple KET
isoforms are colocalized in different rat tissues. The amino-
terminal truncated form vNKETK is expressed in epithelial
tissues, while expression of the most p53-like KET isotype
TAKETQ was detected in skeletal muscle. Expression of a major
KET variant appears to be a cell-type specific rather than a
differentiation specific phenomenon. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
The tumor suppressor p53 ful¢lls a key function concerning
the regulation of cell cycle and apoptosis [1]. Two new pro-
teins named p63/KET and p73 have been described which are
up to 75% identical to p53 in its evolutionary conserved do-
mains [2^4]. Several features of the transcription factor p53,
namely the amino-terminal transactivation domain (TA), the
core DNA binding domain (DBD) and the carboxy-terminal
oligomerization domain (OD) are su⁄ciently conserved in p63
and p73 to bind to p53-responsive elements and to possibly
exert a p53-like e¡ect on gene transcription [5]. In addition a
sterile alpha motif (SAM)-like sequence found at the carboxy-
terminus of p63 and p73 is thought to mediate protein^pro-
tein interactions [6,7]. Transcription assays have indicated that
this p63 carboxy-terminus may exert an inhibitory e¡ect on
the p53-like activity of p63 [8].
In contrast to the single known p53 protein p63 exists in
mammals in six major isotypes, including two variants at the
amino- and three at the carboxy-terminus [9]. An alternative
promotor in intron 3 results in the transcription of amino-
terminal truncated (vN) p63 mRNAs lacking the amino-ter-
minal TA and therefore the ability to mediate p53-like trans-
activation [8].
Alternative splicing of the p63 mRNA at the 3P-end leads to
at least three di¡erent isoforms. In addition to the full length
p63K, deletion of exon 13 during splicing results in p63L pro-
teins which have lost a part of the carboxy-terminal SAM
domain [10]. Alternatively to exon 11, exon 15 can be added
to the 3P-end of exon 10. This shortest p63 isoform termed
p63Q is most similar to the carboxy-terminal end of p53.
Due to di¡erent transactivation activities of the p63 iso-
types [8] and because of the high number of possible, func-
tionally diverse p63 forms it is important to understand the
expression pattern of the splice variants. In the following
study additional splice variants of rat keratinocyte transcrip-
tion factor (KET) and human p63 were identi¢ed, the trans-
activation properties were determined and their tissue distri-
bution was characterized.
2. Materials and methods
2.1. RNA preparation
For RNA isolation tissues were dissected from adult Wistar rats
and stored at 370‡C. The tongue epithelium was prepared directly
after dissection from the tip of rat tongues by collagenase/dispase
treatment [11]. Human tissue samples were removed at autopsy and
total RNA was isolated from all tissues using RNAclean (Hybaid-
AGS, Heidelberg, Germany) according to the manufacturer’s instruc-
tions.
2.2. Rapid ampli¢cation of 5P-cDNA ends (5P-RACE)
Novel 5P-ends of the KET mRNA were identi¢ed with the 5P/3P-
RACE kit (Roche, Mannheim, Germany) according to the manufac-
turer’s description. cDNA synthesis was carried out with rat tongue
total RNA and rat placenta total RNA and the gene speci¢c oligo-
nucleotide KET TA rev (Table 1). The oligonucleotide KET TA3 rev
and the supplied anchor primer were added to the anchor polymerase
chain reaction (PCR). A second round of PCR was performed with
the oligonucleotide 5P-cag aaa atc cca gat atg ctg g-3P and supple-
mented nested primer. PCR products were subcloned and sequenced.
2.3. Ribonuclease protection assay (RPA) and reverse transcription
(RT)-PCR analysis
For RPA, contaminating DNA in the rat tissue total RNA prepa-
ration was removed by DNase I digestion (1 U per 20 Wg RNA, 15
min, 37‡C in 1Utranscription bu¡er, Roche). A total of 20 Wg of
RNA per assay was incubated with 5U105 cpm [K-32P]UTP (Amer-
sham, Freiburg, Germany) labeled KET speci¢c probe at 42‡C over-
night in hybridization bu¡er (RPA-III-Kit, Ambion, Austin, TX,
USA). A glyceraldehyde 3 phosphate dehydrogenase (GAPDH) spe-
ci¢c probe (5U104 cpm) was included as internal control. Riboprobes
were generated by in vitro transcription of 1 Wg linearized plasmid
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DNA with T3 or T7 RNA polymerases (Roche) or SP6 RNA poly-
merase (Stratagene, La Jolla, CA, USA). The KETcore-p probe of
370 base pairs (bp) length was used to hybridize to a 289 bp long
KET mRNA fragment (nucleotides (nt) 1017^1317, GenBank acces-
sion number (GB): Y10258). Expression of TA was analyzed with
TA2KET-p (333 bp) which included a 303 bp long KET TA2 se-
quence (nt 148^450, GB: Y10258). This probe allowed simultaneous
detection of the KET TA1 or KET TA3 splice variant as a 241 bp
long protected cRNA fragment common to all KET TA splice var-
iants. The KET vN splice variant was identi¢ed with the vNKET-p
probe (250 bp) which detected a 170 bp long sequence (nt 1^169, GB:
AJ277447). The 300 bp long KETK-p probe protects a 280 bp frag-
ment of KETK (nt 3208^3487, GB: AJ277447). A 254 bp long KETQ
fragment (nt 1202^1433, GB: AJ277450) was protected by the 310 bp
long transcript named KETQ-p. GAPDH-p (217 bp) hybridized to 200
bp of the GAPDH mRNA (nt 351^550, GB: X02231). RNase treat-
ment was carried out with RNase A/T1 (RPA-III-Kit, Ambion) in a
1:100 dilution in RNase digestion bu¡er (30 min, 37‡C). After sepa-
ration of cRNA fragments in a 8% polyacrylamide gel radioactive
bands were analyzed on the dried gel with the phosphoimager system
Fuji BAS-1800II reader and the software package AIDA (Raytest,
Straubenhardt, Germany).
For RT-PCR 2 Wg of total RNA was reverse transcribed using
Superscript II reverse transcriptase (BRL Life Technologies, Eggen-
stein, Germany) and random hexamer primers (Amersham). Splice
variant speci¢c PCR was carried out with Taq PCR Master Mix
(Qiagen, Hilden, Germany) under the following conditions. 1/20 of
the cDNA was used for PCR ampli¢cation with 35 cycles (94‡C for 30
s, 55‡C for 30 s, 72‡C for 1 min). The temperature program was
modi¢ed for KET TA1 (58‡C for 30 s) and KET TA3 (72‡C for
1 min and 12 s). Speci¢c KET cDNA sequences were ampli¢ed with
the forward and reverse oligonucleotides listed in Table 1. A second
PCR approach with a KET 5P-end forward and 3P-end reverse oligo-
nucleotide identi¢ed the expressed KET 5P/3P-end combination. The
cDNAs TAKETK, TAKETQ, vNKETK and vNKETQ were ampli¢ed
with the ELONGASE Enzyme Mix (BRL Life Technologies) in a
PCR as described above with a modi¢ed elongation step (68‡C for
2 min and 30 s). PCR fragments were visualized with ethidium bro-
mide after separation of equal volumes of each reaction on a 1.2%
(w/v) agarose gel.
2.4. Transcriptional activation assays
For heterologous expression of p63, PCR products of the TA1p63Q,
TA2p63Q, TA4p63Q and TA2p63K coding sequences were cloned in
the pcDNA3.1/Myc-His A vector (Invitrogen, Groningen, The Neth-
erlands). The rat KET TA3 cDNA sequence was added to the 5P-end
of the human TA4p63Q leading to the expression of chimeric proteins
with a rat KET TA3 N-terminus, a human p63 core domain and a
human p63Q C-terminus. The pcDNA3/p53wt (wild type) plasmid was
a gift of Manfred Westphal (UKE, Hamburg, Germany).
Cotransfection of Saos-2 cells with the p63 expression construct, the
p53 reporter plasmid pG13/p21/luciferase (kindly provided by Wolf-
gang Deppert, HPI, Hamburg, Germany) and the pcDNA3.1/Myc-
His/lacZ vector (Invitrogen) was performed with E¡ectene (Qiagen).
After subsequent cultivation for 24 h luciferase activity was quanti¢ed
by chemiluminescence signal detection with the luciferase assay kit
(Promega, Madison, WI, USA) and the MicroLuminat LB 96 P lu-
minometer (EG and G Berthold, Bad-Wildbad, Germany). Transfec-
tion e⁄ciency was evaluated by cotransfection of the pcDNA3.1/Myc-
His/lacZ plasmid and determination of the L-galactosidase activity
with the Galacto-Light Chemiluminescent Reporter Gene Assay (Ap-
plied Biosystems, Bedford, MA, USA). Triplicate experiments were
performed.
3. Results
3.1. Structure of the KET splice variants
Starting with known sequences of human p63 cDNA clones
[12] and the rat KET cDNA [3] new rat KET and human p63
splice variants with altered open reading frames were identi-
¢ed. The 5P-RACE technique was used to elucidate the num-
ber of possible di¡erent 5P-ends of KET and human p63
mRNAs. For clari¢cation, all KET/p63 isoforms including
the transactivation domain encoded by exons 2 and 3 are
named KET/p63 TA. Upstream of exon 2 exist at least three
di¡erent KET exons, 1, 1P and 1Q, which give rise to the N-
termini KET TA1, TA2 and TA3, respectively (Fig. 1A).
Exons 1 and 1P are also found in human p63. The protein-
encoding sequences of exons 1 and 1P are 97% identical be-
tween rat and human while 74% identity is observed in the 5P-
UTRs. Analysis of 5P-RACE products led in all cases to the
identi¢cation of a putative start methionine with a preceding
stop codon in at least one species. Exon 1 encodes four amino
acids in addition to KET/p63 TA. The exon 1P nucleotide
sequence of KET/p63 TA2 determines 21 amino acids and
was described earlier in man, rat and mouse as TA*p63
[2,3,13]. The protein sequences of KET/p63 TA1 and TA2
are 100% identical in the species studied.
A second splice site 8 bp downstream of the intron 1 splice
acceptor site was found in 5P-RACE PCR products of human
skin total RNA (Fig. 1A, arrow).
5P-RACE PCR products and subsequent RT-PCR experi-
ments indicated the existence of another 5P-end for the KET
mRNA in placenta termed KET TA3. KET TA3 PCR prod-
ucts of di¡erent length were identi¢ed including and lacking a
repetitive element between exons 1Q and 2. This insertion of 36
bp shows high identity to rat identi¢er element (ID) sequences
[14]. Exon 1Q appears to be speci¢c for the rat because it was
not detected in human placenta total RNA.
KET mRNAs lacking the transactivation domain are tran-
scribed from an alternative promotor in intron 3. These
mRNAs begin with exon 3P and encode the amino-terminus
KET vN (Fig. 1B). The putative 5P-UTRs of the rat and
human exon 3P identi¢ed by screening of a cDNA library
di¡ered in length by 2 bp and are 81% identical. One amino
Table 1
PCR primers and products for KET
Identi¢cation Forward primer Reverse primer Size (bp) Position (nt) KET GB
KET TA 5P-gcc cat tga ctt gaa ctt tgt g-3P 5P-ctg gaa gga cac atc gaa gct g-3P 338 356^693 Y10258
KET TA1 5P-ggc cac tct atg tca agg gct cta a-3P 5P-gag ccc cag gtt cgt gta ctg tgg-3P 357 210^566 AJ277446
KET TA2 5P-tct gat ggc att tga ccc tat tg-3P 5P-gag ccc cag gtt cgt gta ctg tgg-3P 470 26^495 Y10258
KET TA3 5P-gtg gga taa tgg caa aag gca g-3P 5P-tga gtc ttg cat gcg gat ac-3P 297, 259 ^ ^
KET vN 5P-gga agc aga gaa gag gag agc-3P 5P-ctg gaa gga cac atc gaa gct g-3P 303 74^376 AJ277447
KETQ 5P-ctt cag gaa tga gct tgt gg-3P 5P-gtg gat gtg tgc ctt tga gc-3P 253 1512-(1764) AJ277449
KETK and L 5P-tgg cat ggg agc caa cat tc-3P 5P-tcc agg atc ccc tcc cag at-3P 318, 224 1638^1955 Y10258
TAKETQ 5P-gcc cat tga ctt gaa ctt tgt g-3P 5P-gtg gat gtg tgc ctt tga gc-3P 1388 356^1723 AJ277449
vNKETK 5P-gga agc aga gaa gag gag agc a-3P 5P-aaa gaa atg gtc tgg cgg ag-3P 1719 74^1792 AJ277447
HGPRT 5P-cgt cgt gat tag tga tga tga-3P 5P-ttc aaa tcc aac aaa gtc tgg-3 526 119^644 S79292
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acid exchange is observed in the protein coding region of exon
3P.
The complex splicing events of the KET 5P-end are summa-
rized in Fig. 1C. In general, each long open reading frame
begins in the respective ¢rst exon starting with the two amino
acids MA, MP, MN or ML. However, when any of the ¢rst
exons is added to the alternative splice acceptor in exon 2, the
resulting frame shift would allow translational start of KET
only in exon 2 beginning with the two amino acids MS. This
isoform is termed KET/p63 TA4 and corresponds to TAp63
in Yang et al. [2]. The depicted organization of exons 1 and 1P
was derived from the analysis and comparison of 5P-RACE
clones with the human genomic DNA sequences on BAC
clone 71B1 (Research Genetics, St. Louis, MO, USA). Protein
coding sequences for TA1 and TA2 are located in close vicin-
ity separated by 240 nucleotides. Both coding sequences are
followed by conserved GU splice donor sites. At present it can
not be decided whether exons 1 and 1P arise from a common
primary transcript by alternative usage of the GU splice do-
nor or whether they constitute independent transcripts.
Additional splice variants of the KET mRNA were identi-
¢ed (Fig. 2A) in the central part of the molecule. An alter-
native splice donor at the 3P-end of exon 8 removes 12 bases
from the KET mRNA between the regions encoding the DNA
binding and the tetramerization domain. This truncated exon
8, named 8P, is conserved in mRNAs of man, rat and mouse.
KET mRNAs with exon 8P do not encode the four amino
acids GTKR comprising a putative protein kinase C phos-
phorylation site.
In analogy to p63 extensive splicing is observed at the 3P-
end of the KET mRNA. The KETK mRNA comprises exons
11^14. Removal of exon 13 in the KETL mRNA leads to the
Fig. 1. A and B: Nucleotide sequences and deduced amino acid sequences of rat KET in comparison to the human p63 nucleotide sequences.
The alignment indicates the high identity of the 5P-exons between the two species. The asterisks mark the in-frame stop codons. Amino acids
are abbreviated in single letter code. Start and stop coding nucleotides are shown in white on a black background. The rat ID sequence in the
KET TA3 5P-end is enclosed in a box. Bold vertical bars separate two exons from each other while small vertical bars mark identical nucleo-
tides between the orthologs KET and p63. The arrow points to the alternative splice acceptor site of exon 2. // : Nucleotides of exon 2 omitted.
C: Possible transcription and translation starts for KET are shown in the putative exon/intron structure of the KET gene 5P-region. Open white
boxes highlight translated mRNA sequences while closed black boxes indicate 5P-UTR regions. Arrows indicate possible transcription start sites
while putative translation start methionines and the respective second amino acids are written in capital letters. The positions of exon 1Q and
ID are hypothetical.
Table 2
GenBank accession numbers for the identi¢ed KET splice variants
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loss of a functional SAM domain. Five additional amino acid
codons are followed by a stop codon in the new reading frame
of exon 14.
KETQ is a consequence of exon 15 being alternatively
spliced to the 3P-end of exon 10. The nucleotide sequences
of the described splice variants are deposited at GenBank
(Table 2).
3.2. KET expression in di¡erent rat tissues
KET mRNA expression in rat tissues was investigated with
splice variant speci¢c probes by RPA (Fig. 2B). KET mRNAs
beginning with exon 1P or the KET exon 3P were detected with
the RPA probes TA2KET-p and vNKET-p, respectively.
KETcore-p binds to all KET mRNAs irrespective of their
5P-end or 3P-end. In order to discriminate between the di¡er-
ent 3P-ends of KETQ and KETK, the probes KETQ-p and
KETK-p were used.
KET expression was detected in tongue epithelium, skin,
placenta, thymus, muscle and prostate. Heart was the only
tissue studied without detectable levels of KET expression
(not shown).
RNAs beginning with exon 1P (KET TA2) were found in
skin, thymus and muscle (Fig. 3A, RPA, 303 bp fragment).
The probe TA2KET-p allowed detection of all TA variants
irrespective of the speci¢c ¢rst exon because the entire exon 2
sequence was included. Protected cRNA fragments of 233 bp
and 241 bp length in skin, placenta, thymus and muscle
pointed to the existence of other or alternatively spliced se-
quences. While the 241 bp fragment represents the entire exon
2, the 233 bp long cRNA fragment may be explained by the
usage of the second splice acceptor site in exon 2.
The presence of the TA region encoded by exons 2 and 3 in
all tissues studied except prostate was demonstrated by RT-
PCR (Fig. 3A, KET TA). Exon 1 speci¢c RT-PCR experi-
ments showed that KET TA1 and KET TA2 are coexpressed
in skin, thymus and muscle. Although RPA and RT-PCR
results suggested KET TA mRNA expression in rat placenta,
neither KET TA1 nor KET TA2 5P-ends were detected in this
tissue. PCR ampli¢cation of KET TA3 proved that this var-
iant represented the major TA product of placenta. The two
bands of 259 bp and 297 bp are amplicons with or without the
rat ID sequence. Our preparation of the rat placenta does not
exclude KET TA3 expression in fetal tissues as part of the
placenta.
KET vN sequences starting with exon 3P were found in
tongue epithelium, skin, placenta, thymus and prostate when
examined with RPA and RT-PCR (Fig. 3B). The KET vN
splice variant was not detected in skeletal muscle despite suc-
cessful ampli¢cation of the hypoxanthine guanine phosphor-
ibosyl transferase (HGPRT) control.
As predicted by the results described above, KETcore was
detected in all tissues depicted in Fig. 4A. The RPA revealed
no tissue speci¢c di¡erence in exon 8 versus 8P expression.
Signi¢cant KETK expression was identi¢ed in all investigated
Fig. 2. A: The scheme illustrates the exon/intron structure of the KET gene. The alternative transcript starts are designated TA and vN. An al-
ternative splicing event results in a truncated exon 8 named exon 8P. Di¡erent 3P-ends of the KET mRNA are described as K, L and Q in analo-
gy to p63. B: Two KET mRNAs coding for the isoforms TA2KETQ and vNKETK are shown to indicate the positions of di¡erent hybridiza-
tion probes (-p) used in the RPA. The names refer to their splice variant speci¢city. Boxes in di¡erent shadings highlight known KET
domains.
Fig. 3. KET TA and KET vN expressions were analyzed in di¡er-
ent rat tissues using RPA and RT-PCR. The positions of the full-
length RPA probes remaining after digestion are indicated by -p.
A: The tissue distribution of di¡erent 5P-ends of the KET mRNA
including the transactivation domain was analyzed. RPA detected
the speci¢c expression of KET TA2 (303 bp) and as smaller cRNA
fragments the expression of KET TA1/KET TA3 (241 bp and 233
bp). The RT-PCR experiments discriminated between KET TA1,
TA2 and TA3 expressions. A further RT-PCR experiment shows
the ampli¢cation of all KET TA sequences containing the transacti-
vation domain in exon 2 independent of the ¢rst exon. B: KET
mRNAs resulting from the alternative promotor were detected by
RPA and RT-PCR. Ampli¢cation of a HGPRT fragment was used
as positive control.
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tissues except muscle which is barely positive in RT-PCR ex-
periments (Fig. 4B). KETK speci¢c RT-PCR allowed parallel
detection of the KETL deletion splice variant. The RT-PCR
results suggest a ¢xed ratio of about 10:1 for KETK to KETL.
RPA demonstrated KETQ expression in tongue epithelium,
skin, placenta and muscle but not in prostate (Fig. 4C). The
result was con¢rmed by RT-PCR. In thymus very weak ex-
pression of KETQ was detectable.
The above described RPA and RT-PCR experiments
showed the tissue distribution of individual splice and tran-
scription modules. In order to directly demonstrate the com-
bination of the major amino- and carboxy-termini of KET,
speci¢c primers were used to amplify the entire coding region.
In skeletal muscle, expression of KET was restricted to the
TAKETQ isoform, while in prostate the vNKETK form was
predominant (Fig. 5). All other tissues displayed various iso-
forms. vNKETK as well as TAKETQ were detected in thymus
total RNA. Three splice variants TAKETK, vNKETK and
vNKETQ are present in tongue epithelium. All four splice
variants TAKETK, TAKETQ, vNKETK and vNKETQ are
expressed in skin and placenta (results not shown).
3.3. Transactivation activity of di¡erent KET/p63 N-termini
In order to detect possible di¡erences in the transactivation
potentials of the newly identi¢ed KET/p63 5P-end splice var-
iants, we employed the ability of the p63 DNA binding do-
main to bind to p53-responsive elements in the human p21
gene. The level of transcriptional activation of a luciferase
reporter plasmid containing 2.4 kb promotor sequence of
the human p21 gene was analyzed by transient transfection
of p53 negative Saos-2 cells (Fig. 6). TA1p63Q and the chi-
meric construct TA3p63Q, consisting of the rat KET TA3 N-
terminus, the human core and the human p63Q C-terminus,
transactivate luciferase transcription to about 60% when com-
pared to p53wt. TA2p63Q shows only 40% transactivation
activity while TA2p63K exhibits almost no transactivational
potential possibly due to the autoinhibitory p63K C-terminus.
The transactivation rate of TA4p63Q, the N-terminus of which
is most similar to that of p53, does not di¡er from activity
mediated by p53wt itself [2].
4. Discussion
The variation of the 5P-end of the KET mRNA is remark-
able and raises the question for the translational start methio-
nine that is really used. The ¢rst methionine in exon 2 corre-
sponds to the start methionine in p53 and was suggested as
amino-terminus for p63 TA and p51 [2,15]. It is evident that
the possible KET protein diversity would be drastically re-
duced if all start methionines in the ¢rst exons including
KET TA3 were ignored by the translation apparatus. How-
ever, protein sequences at the extreme amino-terminus of p63
have an in£uence on the transcriptional activity of the protein.
The isoform with the shortest N-terminus, p63 TA4, showed
Fig. 4. RPA and RT-PCR analyses localized KET expression in dif-
ferent rat tissues. A: Detection of KET regardless of the 5P-end and
the 3P-end. KETcore-p allowed the simultaneous detection of exon 8
(247 bp) and 8P (289 bp). Detection of GAPDH monitored the
amount of total RNA in the assay. B: The tissue distribution of
KETK and KETL was analyzed with RPA and RT-PCR. Co-detec-
tion of the GAPDH mRNA was used as a positive control. C: RPA
as well as RT-PCR show the expression pro¢ling of the alternative
exon 15, KETQ.
Fig. 5. RT-PCR analysis identi¢ed the combination of KET splice
variants in skeletal muscle and prostate of rat. A HGPRT cDNA
fragment was ampli¢ed as positive control.
Fig. 6. Transactivation activity of di¡erent p63 N-termini was ana-
lyzed in Saos-2 cells cotransfected with the pG13/p21/luciferase re-
porter plasmid. Quanti¢cation of L-galactosidase expressed from a
second cotransfected plasmid was used to normalize for transfection
e⁄ciency in all experiments. Transactivation is shown relative to the
p53wt activity (100%). Error bars: þ S.D.
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the highest transactivation activity followed by p63 TA1 with
additional 22 amino acids and p63 TA2 with 39 more amino
acids as indicated by our results. Transcription activity might
be in£uenced by the length of the N-terminus of di¡erent p63
TA isoforms. Thus it is conceivable that biological activity of
KET/p63 is not only determined by the choice between TA
and vN isoforms but in addition ¢ne tuned by the use of
di¡erent TA variants. The nearly perfect conservation of ami-
no acids at the extreme amino-terminus in all species studied
strongly supports a possible functional role.
Expression of a major KET isotype seems to be a cell-type
speci¢c phenomenon. This was demonstrated by the predom-
inant detection of the KET isoform vNKETK in prostate and
TAKETQ in skeletal muscle. In complex tissues the relative
amounts of cell types expressing di¡erent KET isotypes will
determine the observable overall expression pattern of KET
variants. An example comes from the analysis of KET expres-
sion in tongue epithelium and skin. Enzymatic preparation of
the tongue epidermis reduces the amount of muscle cells. This
is re£ected by a signi¢cant reduction of KET TA expression in
the tongue epithelium in comparison to skin. While the strong
expression of vNKETK in keratinizing epithelia was reported
earlier [2], detection of TAKETQ expression in skeletal muscle
is a new observation. The existence of this splice variant,
which is most similar to p53, may suggest a possible role of
KET/p63 in terminal di¡erentiation of skeletal muscle cells.
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